Peerview Oncology & Hematology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/RYC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, extensive and nuanced biomarker testing of complex tumors such as non–small cell lung cancer (NSCLC) is essential to determine the best treatment approach for each patient. Targeted therapies are associated with improved outcomes, and the list of relevant therapeutic targets and matched therapies continues to expand, necessitating more granularity and precision in testing. Which tests are appropriate and how should their results be interpreted to inform clinical decisions? How can biomarker testing information guide optimal treatment selection and sequencing throughout the NSCLC disease continuum, including in earlier disease settings in which adjuvant targeted therapy is now available? These and other key questions are answered in this new educational activity. Experts help you prepare to meet the rising challenges and opportunities that

Go online to PeerView.com/PJD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New, modern antibody–drug conjugates (ADCs) have emerged as promising additions to the treatment arsenal for patients with lung cancer, with the first HER2-targeting ADC recently gaining FDA approval for patients with unresectable or metastatic NSCLC whose tumors have HER2 mutations. Clinical trials are also underway with novel ADCs targeting HER3, TROP2, CEACAM5, and MET, among others, and have been yielding encouraging results to date. What are the unique structural and mechanistic features as well as efficacy and safety profiles of these ADCs? Where are they likely to best fit in the NSCLC treatment algorithms? What practical considerations should be taken into account when integrating these therapies into treatment plans? These and other topics are explored in this unique educational activity, based on a recent live symposium, in which experts compete to answer a series of c

Go online to PeerView.com/NEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Although chimeric antigen receptor (CAR-T) cell therapy is primarily administered in the inpatient setting, delivery in the outpatient setting likely represents a more convenient and patient-friendly approach that could expand potentially life-saving treatment access for many patients with hematologic cancers. This “Learning Workshop” activity provides learners with the “tools of the trade” for building an outpatient infrastructure that is capable of expanding patient access to CAR-T therapy. Expert panelists discuss the key data supporting CAR-T therapy in hematologic cancers and provide guidance on principles of outpatient cellular therapy, lessons derived from the outpatient experience with stem cell transplantation, and strategies to overcome barriers to patient selection, adverse events, and adequate staffing. Upon completion of this activity, participants should be better

Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers. Upon completion of this activity, participants should be better

Go online to PeerView.com/FFQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the number of approved treatment strategies in renal cell carcinoma (RCC) grows, there are new opportunities to provide personalized medicine to patients in a variety of settings. Multi-targeted TKIs, immune checkpoint inhibitors, and combination strategies (dual checkpoint blockade and immune checkpoint inhibitor/TKI combinations) are now options in the frontline treatment of advanced disease, while recent data also show that immunotherapy-based combinations may improve survival in patient subpopulations with poor prognostic features. In this activity, based on a recent live symposium, a panel of experts reviews the latest efficacy and safety evidence for approved and emerging strategies for the treatment of patients with advanced RCC in the frontline and refractory settings and engages in discussions of relevant patient cases that will provide insight on bringing these ther

Go online to PeerView.com/PNF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. “Treatment intensification”—or the use of combination treatment strategies—has now become the standard of care for patients with metastatic hormone-sensitive prostate cancer. Shown to extend overall survival beyond single-agent treatment, these combinations of androgen deprivation therapy and other effective treatments such as docetaxel chemotherapy and/or novel androgen axis inhibitors have resulted in regulatory approvals and updates to clinical practice guidelines. Given the range of effective options and more on the horizon, as additional agents and combinations are also being studied in localized and advanced disease, how do clinicians ensure that the right patients are getting the right treatments? In this activity, based on a recent live symposium, expert faculty pair in-depth updates on efficacy and safety data on approved and emerging regimens with case-based discussion

Go online to PeerView.com/CUN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to apply the “new rules” of management to veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) for your patients at risk for this hematopoietic stem cell transplantation (HCT) complication? Find out in this PeerView Clinical Consult video recorded at the 2023 Tandem Meetings. Watch as our panelists give the latest guidance on VOD/SOS management, while discussing adult and pediatric case scenarios designed to inform on risk assessment, diagnostic confirmation, severity grading, and treatment. Throughout, the experts will highlight how modern care principles can confirm a diagnosis, determine the presence of organ dysfunction, and prompt the initiation of timely supportive care and pharmacologic treatment. Don’t miss this opportunity to get the latest, most effective approaches to VOD/SOS management and received CME credit! Upon completion of this ac

Go online to PeerView.com/DWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. First- and second-generation Bruton tyrosine kinase (BTK) inhibitors have transformed the standard of care in many different chronic lymphocytic leukemia (CLL) settings—from treatment-naïve to relapsed disease, as well as in high-risk settings—but are you prepared to fully integrate established and emerging BTKi options into clinical practice, including in the context of community-based care? Find out by viewing this activity, which highlights the clinical decision-making of an academic and a community specialist. Throughout, the panelists will use a series of real-world cases to demonstrate the practicalities of using modern BTKi therapy, provide guidance on the use of next-generation agents, and offer a strong grounding for updated AE management protocols that can ensure safe delivery of care. Upon completion of this activity, participants should be better able to: Summarize e

Go online to PeerView.com/YNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Desmoid tumors are rare but aggressive soft-tissue tumors characterized by locally invasive growth, significant morbidity, and a high rate of recurrence. Considering that they are so rare, there are many challenges related to their recognition and establishment of an accurate diagnosis, and referral to a specialist is essential. Effective therapies have been lacking, but a number of systemic and local therapy options have been assessed in recent trials, with mixed results. Gamma secretase inhibitors are among the most recent promising, rational therapies for desmoid tumors that may transform the management of this disease. Given the transition of care from surgical approaches to more conservative strategies, the emergence of new systemic therapies, and the increasing importance of multidisciplinary coordination of care, there is an urgent need to address key questions and nuance

Go online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive future applications of BTKi in a range of B-cell cancer settings. Don’t miss this educational and informative activity! Upon completion of this activity, participants should be better able to: Cite updated evidence with BTKi-based strategies in CLL/SLL, including longer-term follow-up from pivotal trials, current guidelines, head-to-head data, and outcomes with novel BTK combination plat

Go online to PeerView.com/SZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with immunotherapy, targeted agents, and chemo-free options for follicular lymphoma (FL)? Find out by accessing this activity, where an expert will interpret new evidence supporting the continued integration of bispecific antibodies, CAR-T cell therapy, EZH2 inhibitors, and PI3K inhibitors across multiple lines of therapy in relapsed/refractory FL. Throughout, the expert shares guidance on therapeutic sequencing, safety management, and the future use of innovative combination platforms. Don’t miss this important update from ASH! Upon completion of this activity, participants should be better able to: Summarize evidence surrounding targeted, epigenetic, and immunotherapy options for R/R FL; Integrate modern, evidence-based sequential treatment plans for R/R FL that include immunomodulatory drugs, targeted therapies, epigenetic agents, bis

Go online to PeerView.com/GEP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For patients with recurrent or advanced endometrial cancer, tremendous therapeutic gains have been realized with the incorporation of immune checkpoint inhibitors. Monotherapy and combination approaches have had multiple regulatory approvals in the second-line setting and clinical trials assessing use in the frontline setting are underway. In this CME activity, an expert shares scientific rationale and practical guidance for incorporating molecular testing into patient management to personalize therapeutic selection. Pairing in-depth updates on efficacy and safety data for immunotherapeutic and other novel regimens with case-based discussions of best practices for bringing individualized treatment plans to the clinic, this is a learning opportunity for all in the field of gynecologic oncology. Upon completion of this activity, participants should be better able to: Describe the

Go online to PeerView.com/GQW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with early-stage lung cancer frequently experience disease recurrence within 1 year of receiving curative-intent surgery, representing a significant unmet medical need. Individualized management of patients with NSCLC is based on a number of considerations, including the molecular profile of the patient’s tumor and the benefits and limitations of therapeutic options in the context of the latest evidence. Continued advances with targeted therapies have sparked substantial interest in expanding their use into earlier disease settings, and adjuvant EGFR-targeted therapy has demonstrated remarkable efficacy in early-stage NSCLC, leading to the first regulatory approval of osimertinib as adjuvant therapy after resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. In addition, results from studies in the neoadjuvant setting are

Go online to PeerView.com/FKB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science continues to support a diverse management model for advanced biliary tract cancers (BTCs), including immune-based and targeted platforms, culminating to the first meaningful advancements in frontline therapy for advanced/metastatic BTC in over a decade. Collectively these clinical trends have expanded the use of individualized management strategies, leading to enhanced clinical outcomes for patients with advanced BTC. In this activity, based on a recent live symposium, expert panelists provide data and practical guidance on the current status of care in BTC and new developments related to the use of novel and emerging immunotherapies and targeted options (eg, PD-1 and PD-L1 inhibitors, FGFR, IDH, TRK, and HER2-directed agents). Case presentations explore next-generation care for today’s patients with BTC using personalized upfront and sequential treatment management

Go online to PeerView.com/YRK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immunotherapy revolution has swiftly expanded from advanced lung cancer to the early-stage, resectable, curative-intent setting, and it is radically transforming the standards of care for stage I-III resectable NSCLC. Immunotherapies are now approved in both adjuvant and neoadjuvant settings, and ongoing trials are expected to propel more immunotherapy-based options into early-stage disease settings as well as clarify the best perioperative approaches. What do these developments mean for thoracic surgeons and other members of the multidisciplinary lung cancer care team? How should best practices and standards of care be modernized? What new workflows need to be established to guide individualized treatment selection and make the most of new immunotherapy options to reduce the risk of recurrence and increase the possibility of cure for more patients? This PeerView educational

Go online to PeerView.com/PCK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of personalized medicine, treatment of patients with advanced GI cancers has moved beyond a chemotherapy-centric model to one in which effective treatments can be matched to individual patients based on genomic testing results. What do colorectal and pancreatic cancer providers need to know about baseline testing and personalized treatment strategies, including those that target less common genomic mutations causing RET and NTRK alterations? In this activity, based on a recent live symposium, a panel of experts in GI malignancies presents evidence-based guidance on modern diagnostic protocols and the personalized treatment of fusion-driven cancers. With relevant cases framing the discussion, the panel provides foundational knowledge on tumor-agnostic genomic alterations, updates on genomic testing techniques sensitive enough to capture rare alterations, and str

Go online to PeerView.com/NNK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with hepatocellular carcinoma (HCC) have been nothing short of revolutionary. But what does this revolution in care mean for your patients? In this activity, based on a recent live symposium, a multidisciplinary panel of experts shares best practices for providing personalized medicine that incorporates newer therapy options, including immunotherapy-based combinations in the first-line setting. With discussion of cases drawn from clinical practice, the panel will link the latest data and research to real-world patient care and provide guidance on selecting and sequencing treatments as patients continue to the second line and beyond, and which emerging strategies are set to bring further changes to HCC outcomes. Our panel will also focus on treatment of patients in the early and intermediate stages, including innovative multimodal strategies

Go online to PeerView.com/KTZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared to safely integrate BCMA-targeting options into the care plan for your relapsed/refractory multiple myeloma (MM) patients, including treatment with antibodies, bispecific agents, and CAR-T cell therapy? Find out in this expert-led MasterClass and Case Forum recorded at the Annual Hematology Meeting. Watch our experts as they offer learners guidance on the “road to remission” in MM, and hear how recent advances with BCMA-targeted therapies can directly lead to enhanced outcomes in the most challenging treatment settings. Throughout, the experts also provide case-based guidance on therapy selection with BCMA antibodies and CAR-T therapy, and illustrate how evidence-based practice can optimize delivery of care in pretreated disease. Get on the “road to remission” for your patients, and receive CME/MOC credit today! Upon completion of this activity, participan

Go online to PeerView.com/JBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Less common genomic alterations such as gene fusions represent actionable and important therapeutic targets in a substantial proportion of patients with non–small cell lung cancer (NSCLC). Although they are relatively rare, it is essential to conduct appropriate biomarker testing to identify these alterations because highly effective targeted therapies have become available that can significantly improve patient outcomes versus older targeted therapies or cytotoxic agents. RET fusion–positive NSCLC is one such example. Next-generation, more selective tyrosine kinase inhibitors (TKIs) have demonstrated remarkable efficacy and improved safety in patients with tumors exhibiting RET fusions. However, testing for these fusions and other less common alterations as well as interpreting reports of testing results can be challenging, which can lead to missed opportunities to offer the be

Go online to PeerView.com/YNC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Endocrine therapy, typically with an aromatase inhibitor or fulvestrant plus a CDK4/6 inhibitor, is a mainstay for the management of HR+/HER2- metastatic breast cancer, but many questions still remain about the nuances of optimal use of these and other agents in first- and later-line settings. Furthermore, a number of investigational therapies are showing great promise in HR+/HER2- advanced disease, including novel ER-targeting agents such as oral SERDs, SERMs, SERCAs, PROTACs, and others, as well as antibody–drug conjugates such as those targeting TROP2. It is essential to learn how to best integrate these options into the current treatment arsenal. CDK4/6 inhibition with adjuvant abemaciclib has also changed the standard of care for high-risk patients with earlier-stage disease, but challenges remain, such as determining which patients benefit from this approach, and how to en